611 related articles for article (PubMed ID: 11102254)
1. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
Mehta SR; Yusuf S;
Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254
[TBL] [Abstract][Full Text] [Related]
2. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Peters RJ; Mehta SR; Fox KA; Zhao F; Lewis BS; Kopecky SL; Diaz R; Commerford PJ; Valentin V; Yusuf S;
Circulation; 2003 Oct; 108(14):1682-7. PubMed ID: 14504182
[TBL] [Abstract][Full Text] [Related]
3. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Topol EJ;
Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
[TBL] [Abstract][Full Text] [Related]
5. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
[TBL] [Abstract][Full Text] [Related]
6. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.
Second Chinese Cardiac Study (CCS-2) Collaborative Group
J Cardiovasc Risk; 2000 Dec; 7(6):435-41. PubMed ID: 11189013
[TBL] [Abstract][Full Text] [Related]
7. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
Testa L; Zoccai GB; Porto I; Trotta G; Agostoni P; Andreotti F; Crea F
Am J Cardiol; 2007 Jun; 99(12):1637-42. PubMed ID: 17560866
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis.
Casella G; Ottani F; Pavesi PC; Sangiorgio P; Rubboli A; Galvani M; Fontanelli A; Bracchetti D
Ital Heart J; 2003 Oct; 4(10):677-84. PubMed ID: 14664280
[TBL] [Abstract][Full Text] [Related]
9. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study.
Jneid H; Bhatt DL; Corti R; Badimon JJ; Fuster V; Francis GS
Arch Intern Med; 2003 May; 163(10):1145-53. PubMed ID: 12767950
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
12. Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
Teal PA
Cerebrovasc Dis; 2004; 17 Suppl 3():6-10. PubMed ID: 14730252
[TBL] [Abstract][Full Text] [Related]
13. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
Hirsh J; Bhatt DL
Arch Intern Med; 2004 Oct; 164(19):2106-10. PubMed ID: 15505123
[TBL] [Abstract][Full Text] [Related]
14. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
[TBL] [Abstract][Full Text] [Related]
15. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
16. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
17. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
[TBL] [Abstract][Full Text] [Related]
18. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Keltai M; Tonelli M; Mann JF; Sitkei E; Lewis BS; Hawken S; Mehta SR; Yusuf S;
Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):312-8. PubMed ID: 17446813
[TBL] [Abstract][Full Text] [Related]
19. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
Mahoney EM; Mehta S; Yuan Y; Jackson J; Chen R; Gabriel S; Lamy A; Culler S; Caro J; Yusuf S; Weintraub WS;
Am Heart J; 2006 Jan; 151(1):219-27. PubMed ID: 16368322
[TBL] [Abstract][Full Text] [Related]
20. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
